Pathogenesis of Liver Fibrosis
The DOI matches its Crossref record; 220 of the 222 references it cites were found in a registry or an index, and 2 are not checked yet.
Abstract
Liver fibrosis is a major cause of morbidity and mortality worldwide due to chronic viral hepatitis and, more recently, from fatty liver disease associated with obesity. Hepatic stellate cell activation represents a critical event in fibrosis because these cells become the primary source of extracellular matrix in liver upon injury. Use of cell-culture and animal models has expanded our understanding of the mechanisms underlying stellate cell activation and has shed new light on genetic regulation, the contribution of immune signaling, and the potential reversibility of the disease. As pathways of fibrogenesis are increasingly clarified, the key challenge will be translating new advances into the development of antifibrotic therapies for patients with chronic liver disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“STAT3, a member of the STATs family, is a key transcriptional mediator of cellular processes [43, 44].”
From Saikosaponin b1 Attenuates Liver Fibrosis by Blocking STAT3/Gli1 Interaction and Inducing Gli1 Degradation (2025) · cites this paper as [43]
In the citing paper
“they may also derive from portal fibroblasts, bone marrow-derived cells, circulating fibrocytes, [7] and by the controversially discussed epithelial-tomesenchymal (EMT) [8,9] or endothelial-to-mesenchymal (EndoTM) transition.[10,11]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [7]
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Origins and Mechanisms of miRNAs and siRNAs
Carthew, R. W., & Sontheimer, E. J. (2009) · Cell · doi:10.1016/j.cell.2009.01.035 · Cited by 5,018
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Self-citationMany roads to maturity: microRNA biogenesis pathways and their regulation
Winter, J., Jung, S., Keller, S., Gregory, R. I., & Diederichs, S. (2009) · Nature Cell Biology · doi:10.1038/ncb0309-228 · Cited by 2,656
Epithelial-mesenchymal transition and its implications for fibrosis
Kalluri, R., & Neilson, E. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320530 · Cited by 2,649
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Self-citationEndothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222
Bendelac, A., Savage, P. B., & Teyton, L. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141711 · Cited by 2,155
Research works printed but not linked: 15
- 10.1172/jci200112373 · DOI · Paper page
- 10.1055/s-2001-17556 · DOI · Paper page
- Stupack DG., 2007, Oncology, 21, 6
- Hehlgans S, 2007, Biochim. Biophys. Acta, 1775, 163
- Omenetti A, 2008, J. Clin. Investig., 118, 3331
- Pinzani M, 1996, Am. J. Pathol., 148, 785
- Sims DE., 1991, Can. J. Cardiol., 7, 431
- Thimgan MS, 1999, Am. J. Physiol., 277, G137
- 10.1136/gut.2005.088690 · DOI · Paper page
- Gao B., 2005, Cell Mol. Immunol., 2, 92
- Anania FA, 1995, Hepatology, 21, 1640
- Connolly MK, 2009, J. Clin. Investig., 119, 3213
- Seki E, 2009, J. Clin. Investig., 119, 1858
- McCrudden R, 2000, Histol. Histopathol., 15, 1159
- 10.1002/hep.23046 · DOI · Paper page
Cited by
Items 201–300 of 1,007
Nevzorova, Y. A., Hu, W., Cubero, F. J., Haas, U., Freimuth, J., Tacke, F., Trautwein, C., & Liedtke, C. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.06.001 · Cited by 86
Tang, M., Chen, Y., Li, B., Sugimoto, H., Yang, S., Yang, C., LeBleu, V. S., McAndrews, K. M., & Kalluri, R. (2021) · The FASEB Journal · doi:10.1096/fj.202002777rr · Cited by 86
Circular RNA circFBXW4 suppresses hepatic fibrosis via targeting the miR-18b-3p/FBXW7 axis
Chen, X., Li, H.-D., Bu, F., Li, X., Chen, Y., Zhu, S., Wang, J., Chen, S., Sun, Y.-Y., Pan, X., et al. (2020) · Theranostics · doi:10.7150/thno.42423 · Cited by 86
Wijesundera, K. K., Izawa, T., Tennakoon, A. H., Murakami, H., Golbar, H. M., Katou-Ichikawa, C., Tanaka, M., Kuwamura, M., & Yamate, J. (2014) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2014.04.003 · Cited by 86
ECM roles in the function of metabolic tissues
Huang, G., & Greenspan, D. S. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.09.006 · Cited by 78
Juliano, R. L., Carver, K., Cao, C., & Ming, X. (2013) · Journal of Drug Targeting · doi:10.3109/1061186x.2012.740674 · Cited by 79
Assessment of liver fibrosis by variable flip angle T1 mapping at 3.0T
Li, Z., Sun, J., Hu, X., Huang, N., Han, G., Chen, L., Zhou, Y., Bai, W., & Yang, X. (2015) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25030 · Cited by 84
Chen, L., Li, L., Chen, J., Li, L., Zheng, Z., Ren, J., & Qiu, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.6466 · Cited by 83
“The same pathological processes behind fibrosis have also been linked with hepatocellular carcinoma (HCC) [1, 2].”
BackgroundQu, K., Huang, Z., Lin, T., Liu, S., Chang, H., Yan, Z., Zhang, H., & Liu, C. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00300 · Cited by 75
AMPK: a novel target for treating hepatic fibrosis
Liang, Z., Li, T. X., Jiang, S., Xu, J., Di, W., Yang, Z. P., Hu, W., & Yang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.19376 · Cited by 83
Stem cells for treatment of liver fibrosis/cirrhosis: clinical progress and therapeutic potential
Liu, P., Mao, Y., Xie, Y., Wei, J., & Yao, J. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03041-5 · Cited by 82
Telocytes in human liver fibrosis
Fu, S., Wang, F., Cao, Y. W., Huang, Q., Xiao, J., Yang, C., & Popescu, L. M. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12542 · Cited by 82
Zeng, C., Wang, Y., Xie, C., Sang, Y., Li, T.-J., Zhang, M., Wang, R., Zhang, Q., Zheng, L., & Zhuang, S. (2015) · Oncotarget · doi:10.18632/oncotarget.3652 · Cited by 83
Gu, Y.-J., Sun, W., Zhang, S., Li, X., & Wei, W. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2692 · Cited by 81
Progress on the Function and Application of Thymosin β4
Yuan, X., Ye, Y., Zuo, H., & Li, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.767785 · Cited by 81
“It is characterized by collagen and extracellularmatrix protein deposition in the liver tissues (107).”
BackgroundPan, T., Wang, P.-W., Leu, Y., Wu, T.-H., & Wu, T.-S. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.12.028 · Cited by 81
MicroRNA-17-5p-activated Wnt/β-catenin pathway contributes to the progression of liver fibrosis
Yu, F., Lu, Z., Huang, K., Wang, X., Xu, Z., Chen, B., Dong, P., & Zheng, J. (2016) · Oncotarget · doi:10.18632/oncotarget.6447 · Cited by 78
SENP1 prevents steatohepatitis by suppressing RIPK1-driven apoptosis and inflammation
Yan, L., Zhang, T., Wang, K., Chen, Z., Yang, Y., Shan, B., Sun, Q., Zhang, M., Zhang, Y., Zhong, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34993-0 · Cited by 80
Nissim, O., Melis, M., Diaz, G., Kleiner, D. E., Tice, A., Fantola, G., Zamboni, F., Mishra, L., & Farci, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049611 · Cited by 75
Serious Non-AIDS events: Immunopathogenesis and interventional strategies
Hsu, D. C., Sereti, I., & Ananworanich, J. (2013) · AIDS Research and Therapy · doi:10.1186/1742-6405-10-29 · Cited by 81
Zhang, F., Hao, M., Jin, H., Yao, Z., Lian, N., Wu, L., Shao, J., Chen, A., & Zheng, S. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13701 · Cited by 80
LOXL2—A New Target in Antifibrogenic Therapy?
Puente, A., Fortea, J. I., Cabezas, J., Arias Loste, M. T., Iruzubieta, P., Llerena, S., Huelin, P., Fábrega, E., & Crespo, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071634 · Cited by 79
It’s all about the spaces between cells: role of extracellular matrix in liver fibrosis
Khurana, A., Sayed, N., Allawadhi, P., & Weiskirchen, R. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-2948 · Cited by 79
Preventive and therapeutic role of betaine in liver disease: A review on molecular mechanisms
Wang, C., Ma, C., Gong, L., Dai, S., & Li, Y. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174604 · Cited by 80
Zhao, Y., Ma, X., Wang, J., He, X., Hu, Y. W., Zhang, P., Wang, R., Li, R., Gong, M., Luo, S., et al. (2014) · Molecules · doi:10.3390/molecules191118767 · Cited by 79
Influence of Liver Fibrosis on Lobular Zonation
Ghallab, A., Myllys, M., Holland, C. H., Zaza, A., Murad, W., Hassan, R. A. R. A., Ahmed, Y. A., Abbas, T., Abdelrahim, E. A., Schneider, K. M., et al. (2019) · Cells · doi:10.3390/cells8121556 · Cited by 79
Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis
Hoffmann, C., Djerir, N. E. H., Danckaert, A., Fernandes, J., Roux, P., Charrueau, C., Lachagès, A.-M., Charlotte, F., Brocheriou, I., Clément, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60615-0 · Cited by 78
Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis
Horowitz, J. C., Ajayi, I. O., Kulasekaran, P., Rogers, D. S., White, J. B., Townsend, S. K., White, E. S., Nho, R. S., Higgins, P. D. R., Huang, S. K., et al. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.10.011 · Cited by 78
CD11b+ Gr1+ bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice
Suh, Y.-G., Kim, J. K., Byun, J.-S., Yi, H.-S., Lee, Y.-S., Eun, H. S., Kim, S. Y., Han, K.-H., Lee, K. S., Duester, G., et al. (2012) · Hepatology · doi:10.1002/hep.25817 · Cited by 74
Self-citationMatrix Mechanics as Regulatory Factors and Therapeutic Targets in Hepatic Fibrosis
Chen, G., Xia, B., Fu, Q., Huang, X., Wang, F., Chen, Z., & Lv, Y. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.37500 · Cited by 71
Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection
Zhang, Z., Zhang, J., Wang, L., & Wang, F. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06940.x · Cited by 77
Hepatic Fibrosis and the Microenvironment: Fertile Soil for Hepatocellular Carcinoma Development
Wallace, M. C., & Friedman, S. L. (2014) · Gene Expression · doi:10.3727/105221614x13919976902057 · Cited by 79
Self-citationFinkelmeier, F., Kronenberger, B., Zeuzem, S., Piiper, A., & Waidmann, O. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132119 · Cited by 77
Substrate Stiffness-Driven Membrane Tension Modulates Vesicular Trafficking via Caveolin-1
Lachowski, D., Matellan, C., Gopal, S., Cortes, E., Robinson, B. K., Saiani, A., Miller, A. F., Stevens, M. M., & del Río Hernández, A. E. (2022) · ACS Nano · doi:10.1021/acsnano.1c10534 · Cited by 76
Evodiamine and rutaecarpine from Tetradium ruticarpum in the treatment of liver diseases
Li, X., Ge, J., Zheng, Q., Zhang, J., Sun, R., & Liu, R. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153180 · Cited by 76
Basso, B. D. S., Haute, G. V., Ortega‐Ribera, M., Luft, C., Antunes, G. L., Bastos, M. S., Carlessi, L. P., Levorse, V. G. S., Cassel, E., Donadio, M. V. F., et al. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114433 · Cited by 76
Blood platelets and inflammation: Their relationship with liver and digestive diseases
Ripoche, J. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.02.012 · Cited by 76
Targeting autophagy for the treatment of liver diseases
Ni, H., Williams, J. A. R., Yang, H., Shi, Y., Fan, J., & Ding, W. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.07.003 · Cited by 77
Liu, Z., Lian, B., Dong, Q., Sun, H., Wei, J., Sheng, Y., Li, W., Li, Y., Xie, L., Liu, L., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.01.027 · Cited by 76
Feng, J., Chen, K., Xia, Y., Wu, L., Li, J., Li, S., Wang, W., Lu, X., Liu, T., & Guo, C.-Y. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s162950 · Cited by 76
Arctic Fox Influence on a Seabird Community in Labrador: A Natural Experiment
Birkhead, T. R., & Nettleship, D. N. (1995) · The Wilson Journal of Ornithology · doi:10.5281/zenodo.16493673 · Cited by 76
Huang, M., Chang, A., Choi, M., Zhou, D., Anania, F. A., & Shin, C. H. (2014) · Hepatology · doi:10.1002/hep.27285 · Cited by 75
Shi, J., Zhao, J., Zhang, X., Cheng, Y., Hu, J., Li, Y., Zhao, X., Shang, Q., Sun, Y., Tu, B., et al. (2017) · Scientific Reports · doi:10.1038/srep44544 · Cited by 61
Feng, J., Wang, C., Liu, T., Li, J., Wu, L., Yu, Q., Li, S., Zhou, Y., Zhang, J., Chen, J., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14543 · Cited by 75
Progranulin attenuates liver fibrosis by downregulating the inflammatory response
Yoo, W., Lee, J., Noh, K. H., Lee, S., Jung, D., Kabir, M. H., Park, D., Lee, C., Kwon, K., Kim, J.-S., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1994-2 · Cited by 75
Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis
Han, X., Wu, Y., Yang, Q., & Cao, G. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107791 · Cited by 75
Liu, J., Liu, J., Mu, W., Ma, Q., Zhai, X., Jin, B., Liu, Y., & Zhang, N. (2024) · ACS Nano · doi:10.1021/acsnano.4c02380 · Cited by 74
Yu, Q., Cheng, P., Wu, J., & Guo, C. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16267 · Cited by 74
Zhai, X., Yan, K., Fan, J., Niu, M., Zhou, Q., Zhou, Y., Chen, H., & Zhou, Y. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12114 · Cited by 69
Lee, J., Jang, E. J., Seo, H. L., Ku, S., Lee, J. R., Shin, S. S., Park, S., Kim, S. C., & Kim, Y. W. (2014) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.10.005 · Cited by 74
Han, C. Y., Koo, J. H., Kim, S. H., Gardenghi, S., Rivella, S., Strnad, P., Hwang, S. J., & Kim, S. G. (2016) · Nature Communications · doi:10.1038/ncomms13817 · Cited by 74
Martin-Mateos, R., De Assuncao, T. M., Arab, J. P., Jalan-Sakrikar, N., Yaqoob, U., Greuter, T., Verma, V. K., Mathison, A. J., Cao, S., Lomberk, G., et al. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2018.09.005 · Cited by 73
“005 Ccharacterized by the accumulation of extracellular matrix (ECM), chronic inflammation, and fibrosis.(1) Hepatic stellate cells (HSCs) constitute the primary source of ECM once they transdifferentiate into myofibroblasts.”
BackgroundYovchev, M. I., Xue, Y., Shafritz, D. A., Locker, J., & Oertel, M. (2014) · Hepatology · doi:10.1002/hep.26615 · Cited by 73
Jantararussamee, C., Rodniem, S., Taweechotipatr, M., Showpittapornchai, U., & Pradidarcheep, W. (2020) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-020-09663-6 · Cited by 73
Engineering hydrogels for personalized disease modeling and regenerative medicine
Tayler, I. M., & Stowers, R. S. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.04.020 · Cited by 73
Zhang, F., Lu, Y., & Zheng, S. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.11.008 · Cited by 74
Yang, Y., Wu, X.-Q., Li, W.-X., Huang, H.-M., Li, H.-D., Pan, X.-Y., Li, X.-F., Huang, C., Meng, X.-M., Zhang, L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0383-0 · Cited by 72
Ballway, J. W., & Song, B.-J. (2021) · Antioxidants · doi:10.3390/antiox10030384 · Cited by 72
Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis
Barcena-Varela, M., Colyn, L., & Fernandez-Barrena, M. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102507 · Cited by 72
“Therefore, following liver injury, HSCs become activated, acquiring a phenotype characterized by the loss of retinoid droplets, increased proliferation and contractile activity, and the release of proinflammatory, profibrogenic, and promitogenic cytokines [8,10,13].”
BackgroundInfluentialTet2 deficiency drives liver microbiome dysbiosis triggering Tc1 cell autoimmune hepatitis
Pandey, S. P., Bender, M. J., McPherson, A. C., Phelps, C. M., Sanchez, L. M., Rana, M., Hedden, L., Sangani, K. A., Chen, L., Shapira, J. H., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.05.006 · Cited by 72
Determining the effector response to cell death
Rothlin, C. V., Hille, T. D., & Ghosh, S. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-00456-0 · Cited by 72
Understanding the complex macrophage landscape in MASLD
Ponti, F. F. D., Liu, Z., & Scott, C. L. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101196 · Cited by 72
Adiponectin as an Anti-fibrotic and Anti-inflammatory Adipokine in the Liver
Park, P.-H., Sanz-Garcia, C., & Nagy, L. E. (2015) · Current Pathobiology Reports · doi:10.1007/s40139-015-0094-y · Cited by 69
Therapeutic mechanism of Yīn-Chén-Hāo decoction in hepatic diseases
Li, J., Cao, H., Sun, L., Sun, R., Wu, C., Bian, Y., Dong, S., Liu, P., & Sun, M. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i7.1125 · Cited by 72
Mechanical homeostasis imbalance in hepatic stellate cells activation and hepatic fibrosis
Zhao, Y.-Q., Deng, X.-W., Xu, G.-Q., Lin, J., Lu, H.-Z., & Chen, J. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1183808 · Cited by 71
“After the liver injury, the low-density basement membrane-like matrix in the Disse space is destroyed, and the original collagen types IV and VI are replaced by collagen types I, III, and fibrin (Hernandez-Gea and Friedman, 2011).”
BackgroundMolecular Mechanisms and Potential New Therapeutic Drugs for Liver Fibrosis
Wang, F.-D., Zhou, J., & Chen, E.-Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.787748 · Cited by 71
Mogler, C., Wieland, M., König, C., Hu, J., Runge, A., Korn, C., Besemfelder, E., Breitkopf‐Heinlein, K., Komljenovic, D., Dooley, S., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404246 · Cited by 71
Gong, L., Wei, F., Gonzalez, F. J., & Li, G. (2023) · Hepatology · doi:10.1097/hep.0000000000000182 · Cited by 71
Telocyte implications in human pathology: An overview
Ibba‐Manneschi, L., Rosa, I., & Manetti, M. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.01.022 · Cited by 71
The role of Th17 cells in viral infections
Aghbash, P. S., Hemmat, N., Nahand, J. S., Shamekh, A., Memar, M. Y., Babaei, A., & Baghi, H. B. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107331 · Cited by 70
Chowdhury, M. R. H., Sagor, M. A. T., Tabassum, N., Potol, M. A., Hossain, H., & Alam, M. A. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/598179 · Cited by 70
Cellular crosstalk in fibrosis: Insights into macrophage and fibroblast dynamics
Froom, Z. S. C. S., Callaghan, N. I., & Huyer, L. D. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110203 · Cited by 71
da Costa, A. N., Plymoth, A., Santos‐Silva, D., Ortiz‐Cuaran, S., Camey, S. A., Guilloreau, P., Sangrajrang, S., Khuhaprema, T., Mendy, M. E., Lesi, O. A., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28953 · Cited by 69
Paeoniflorin alleviates liver fibrosis by inhibiting HIF-1α through mTOR-dependent pathway
Zhao, Y., Ma, X., Wang, J., Zhu, Y., Li, R., Wang, J., He, X., Shan, L., Wang, R., Wang, L., et al. (2014) · Fitoterapia · doi:10.1016/j.fitote.2014.10.009 · Cited by 69
Common pathway signature in lung and liver fibrosis
Makarev, E., Izumchenko, E., Aihara, F., Wysocki, P., Zhu, Q., Buzdin, A. A., Sidransky, D., Zhavoronkov, A. A., & Atala, A. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1152435 · Cited by 69
Ferroptosis contribute to hepatic stellate cell activation and liver fibrogenesis
Cho, S. S., Yang, J. H., Lee, J., Baek, J. S., Ku, S., Cho, I. J., Kim, K. M., & Ki, S. H. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.11.011 · Cited by 68
Fausther, M., Sheung, N., Saiman, Y., Bansal, M. B., & Dranoff, J. A. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00015.2012 · Cited by 68
“Liver myofibroblasts are the primary cells responsible for the extensive ECM accumulation observed in liver fibrosis.”
BackgroundSerotonin: A double-edged sword for the liver?
Lesurtel, M., Soll, C., Humar, B., & Clavien, P. (2011) · The Surgeon · doi:10.1016/j.surge.2011.11.002 · Cited by 68
Mentink–Kane, M. M., Cheever, A. W., Wilson, M. S., Madala, S. K., Beers, L. M., Ramalingam, T. R., & Wynn, T. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.08.008 · Cited by 59
A 3D alcoholic liver disease model on a chip
Lee, J., Choi, B., No, D. Y., Lee, G., Lee, S.-R., Oh, H., & Lee, S.-H. (2016) · Integrative Biology · doi:10.1039/c5ib00298b · Cited by 65
Liver fibrosis: the 2017 state of art
Caviglia, G. P., Rosso, C., Fagoonee, S., Saracco, G. M., & Pellicano, R. (2017) · Panminerva Medica · doi:10.23736/s0031-0808.17.03359-6 · Cited by 68
Chen, L., Wei, X., Gu, D., Xu, Y., & Zhou, H. (2023) · Cancer Letters · doi:10.1016/j.canlet.2022.216048 · Cited by 61
Hedgehog signaling pathway as key player in liver fibrosis: new insights and perspectives
Yang, J.-J., Tao, H., & Li, J. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.927443 · Cited by 65
Fang, L., Huang, C. Z., Meng, X., Wu, B., Ma, T., Liu, X., Zhu, Q., Zhan, S., & Li, J. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.08.006 · Cited by 67
Interleukin-17: Friend or foe in organ fibrosis
Ramani, K., & Biswas, P. S. (2019) · Cytokine · doi:10.1016/j.cyto.2018.11.003 · Cited by 66
“One of the primary event in the initiation of hepatic fibrosis is the activation of hepatic stellate cells (HSCs) [63], which results in the overproduction of ECM.”
BackgroundJi, J., Yu, Q., Dai, W., Wu, L., Feng, J., Zheng, Y., Li, Y., & Guo, C. (2021) · PPAR Research · doi:10.1155/2021/6651839 · Cited by 67
“Liver fibrosis is a chronic pathological change caused by a variety of reasons, such as chronic infection by hepatotropic viruses, excess alcohol consumption, nonalcoholic fatty liver disease, autoimmune liver diseases, and hereditary disease, and is a necessary stage for the development of many liver diseases to live…”
BackgroundInterleukin-24 Immunobiology and Its Roles in Inflammatory Diseases
Zhong, Y., Zhang, X., & Chong, W. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020627 · Cited by 66
“The associated excessive tissue damage and inflammatory environment activates monocytes, hepatocytes, Kupffer cells, and stellate cells for the production of proinflammatory molecules and fibrogenic factors [60].”
BackgroundVersican: a novel modulator of hepatic fibrosis
Bukong, T. N., Maurice, S. B., Chahal, B., Schaeffer, D. F., & Winwood, P. J. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2015.152 · Cited by 66
Qin, L., Qin, J., Zhen, X., Yang, Q., & Huang, L. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.091 · Cited by 66
Regulation of hepatocyte identity and quiescence
Berasain, C., & Avila, M. A. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1970-7 · Cited by 68
“Liver cirrhosis involves the progressive deterioration of hepatic architecture, with the substitution of the parenchymal component by abundant extracellular matrix (ECM) and the appearance of regenerative hepatocellular nodules [169].”
BackgroundCDKN2a/p16 Antagonizes Hepatic Stellate Cell Activation and Liver Fibrosis by Modulating ROS Levels
Lv, F., Li, N., Kong, M., Wu, J., Fan, Z., Miao, D., Xu, Y., Ye, Q., & Wang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00176 · Cited by 65
Luo, S., Yang, Y., Zhao, T., Zhang, R., Fang, C., Li, Y., Zhang, Z., & Gong, T. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c19269 · Cited by 65
Huang, J., Huang, H., Wang, Y., Xu, B., Lin, M., Han, S., Yuan, Y., Wang, Y., & Shuai, X. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122134 · Cited by 65
Deng, Y., Xiong, X.-Z., & Cheng, N. (2012) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(12)60210-0 · Cited by 65
Liu, Y., She, W., Wang, F., Li, J., Wang, J., & Jiang, W. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.09.024 · Cited by 65
Engineering in vitro models of hepatofibrogenesis
Mazza, G., Al‐Akkad, W., & Rombouts, K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.018 · Cited by 66
González-Ponce, H. A., Rincón‐Sánchez, A. R., Jaramillo‐Juárez, F., & Moshage, H. J. (2018) · Nutrients · doi:10.3390/nu10020117 · Cited by 66
Lian, N., Jiang, Y., Zhang, F., Jin, H., Lu, C., Wu, X., Lu, Y., & Zheng, S. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.59 · Cited by 64
Potent natural products and herbal medicines for treating liver fibrosis
Chen, S.-R., Chen, X.-P., Lu, J.-J., Wang, Y., & Wang, Y.-T. (2015) · Chinese Medicine · doi:10.1186/s13020-015-0036-y · Cited by 64
Role of the CXCR6/CXCL16 axis in autoimmune diseases
Bao, N., Fu, B., Zhong, X., Jia, S., Ren, Z., Wang, H., Wang, W., Shi, H. R., Li, J., Ge, F., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110530 · Cited by 66
Metadata
- Authors
- Hernandez-Gea, V., & Friedman, S. L.
- Affiliations
- Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029;
- Icahn School of Medicine at Mount Sinai (US)
- ORCID
- Friedman, Scott L.
- Venue
- Annual Review of Pathology: Mechanisms of Disease
- Publisher
- Annual Reviews
- Published
- 2011-02-28
- Volume
- 6
- Issue
- 1
- Pages
- 425-456
- ISSN
- 1553-4006 (ISSN-L)
- 1553-4014
- OpenAlex
- W2142988890
- Cited by
- 1,809
- References
- 220
- Citations by year
- 2026: 81 · 2025: 123 · 2024: 121 · 2023: 112 · 2022: 148 · 2021: 174 · 2020: 145 · 2019: 119 · 2018: 117 · 2017: 131 · 2016: 136 · 2015: 124 · 2014: 97 · 2013: 76 · 2012: 67
- FWCI
- 10.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annual Review of Pathology Mechanisms of Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- liver fibrosis, hepatic stellate cell activation, extracellular matrix, chronic viral hepatitis, hepatic steatosis, obesity, immune signaling, genetic control, fibrosis reversibility, antifibrotic therapy, chronic liver disease
- MeSH terms
- Humans, Liver, Liver Cirrhosis, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.